Expert opinion on drug safety

Keyphrases

Publications

volume 23, number 5, 2024

Cai-Lu Lei, Xiao-Long Gui, Lin-Yu Wang, You-Jia Guo, Yan Li
Analysis of drug-induced posterior reversible encephalopathy syndrome using the food and drug administration adverse drug events reporting system database. Expert opinion on drug safety 23 (5) (2024)
Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Valeria Carinci, Gianni Casella, Linda Vignozzi, Alessandra Sforza, Mario Maggi
Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis. Expert opinion on drug safety 23 (5) (2024)
Roger S McIntyre
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas. Expert opinion on drug safety 23 (5) (2024)
Ahmad Z Al Meslamani
Adverse drug event reporting among women: uncovering disparities in underserved communities. Expert opinion on drug safety 23 (5) (2024)
Sichun Xiang, Rongbin Shen, Jingjing Xiang, Ni Zhu, Jianyou Gu, Jianping Shen, Yu Zhang, Hangping Ge
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy. Expert opinion on drug safety 23 (5) (2024)
Dehua Zhao, Xiaoqing Long, Jisheng Wang
Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System. Expert opinion on drug safety 23 (5) (2024)
Irina Luzko, Olga P Nyssen, Leticia Moreira, Javier P Gisbert
Safety profile of Helicobacter pylori eradication treatments: literature review and updated data of the European Registry on Helicobacter pylori management (Hp-EuReg). Expert opinion on drug safety 23 (5) (2024)
Harriet Dickinson, Jan Feifel, Katoo Muylle, Taichi Ochi, Enriqueta Vallejo-Yagüe
Learning with an evolving medicine label: how artificial intelligence-based medication recommendation systems must adapt to changing medication labels. Expert opinion on drug safety 23 (5) (2024)
Sichun Xiang, Rongbin Shen, Jingjing Xiang, Ni Zhu, Jianyou Gu, Jianping Shen, Yu Zhang, Hangping Ge
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy. Expert opinion on drug safety 23 (5) (2024)
Khushboo Bisht, Bharathi Mohan, Basavaraj Jatteppanavar, Hannah Theresa Sony, Shailendra Handu, Minakshi Dhar
An observational study of root-cause analysis of medication errors in elderly with methotrexate toxicity. Expert opinion on drug safety 23 (5) (2024)
Khushboo Bisht, Bharathi Mohan, Basavaraj Jatteppanavar, Hannah Theresa Sony, Shailendra Handu, Minakshi Dhar
An observational study of root-cause analysis of medication errors in elderly with methotrexate toxicity. Expert opinion on drug safety 23 (5) (2024)
Xiaolin Yun, Yingying Zhou, Danna Wu, Yuanbo Liu, Qiongshi Wu
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab. Expert opinion on drug safety 23 (5) (2024)
Harriet Dickinson, Jan Feifel, Katoo Muylle, Taichi Ochi, Enriqueta Vallejo-Yagüe
Learning with an evolving medicine label: how artificial intelligence-based medication recommendation systems must adapt to changing medication labels. Expert opinion on drug safety 23 (5) (2024)
Roger S McIntyre
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas. Expert opinion on drug safety 23 (5) (2024)
Qian Cheng, Xuan Shi, Yazheng Zhao, Shupeng Zou, Minghui Sun
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system. Expert opinion on drug safety 23 (5) (2024)
Weichui Zhang, Mianhai Chen, Xiaolin Cai, Mengting Zhang, Mianda Hu, Yanghui Hu, Yurong Yang, Jinfeng Zhu, Yi-Kuan Du, Chun Yang
Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system. Expert opinion on drug safety 23 (5) (2024)
Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Valeria Carinci, Gianni Casella, Linda Vignozzi, Alessandra Sforza, Mario Maggi
Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis. Expert opinion on drug safety 23 (5) (2024)
Irina Luzko, Olga P Nyssen, Leticia Moreira, Javier P Gisbert
Safety profile of Helicobacter pylori eradication treatments: literature review and updated data of the European Registry on Helicobacter pylori management (Hp-EuReg). Expert opinion on drug safety 23 (5) (2024)

volume 23, number 6, 2024

Rouhin Sen, Maria Riofrio, Jasvinder A Singh
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis. Expert opinion on drug safety 23 (6) (2024)
Jae Hui Kim
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice. Expert opinion on drug safety 23 (6) (2024)
Pier Paolo Bocchino, Filippo Angelini, Guglielmo Gallone, Simone Frea, Gaetano Maria De Ferrari
The cardiovascular safety of sodium nitroprusside in acute heart failure. Expert opinion on drug safety 23 (6) (2024)
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Jae Hui Kim
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice. Expert opinion on drug safety 23 (6) (2024)
Wolfgang Strube, Elias Wagner, Jurjen J Luykx, Alkomiet Hasan
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective. Expert opinion on drug safety 23 (6) (2024)
Kazumasa Yamamoto, Shun Yamamoto, Ken Kato
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Wolfgang Strube, Elias Wagner, Jurjen J Luykx, Alkomiet Hasan
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective. Expert opinion on drug safety 23 (6) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Rouhin Sen, Maria Riofrio, Jasvinder A Singh
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis. Expert opinion on drug safety 23 (6) (2024)

volume 23, number 7, 2024

Timothy Tanzer, Betty Pham, Nicola Warren, Michael Barras, Steve Kisely, Dan J Siskind
Overcoming clozapine's adverse events: a narrative review of systematic reviews and meta-analyses. Expert opinion on drug safety 23 (7) (2024)
Ashley Wang, Alexandra Tsivitis, Sijia Ma, Zhaosheng Jin, Ehab Al Bizri, Robert Moore
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants. Expert opinion on drug safety 23 (7) (2024)
P M L A van den Bemt, E P van Puijenbroek, F P A M van Hunsel
How could employing the patient perspective transform pharmacovigilance? Expert opinion on drug safety 23 (7) (2024)
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta, Mario Cazzola
An overview of the efficacy and safety of β 2 -adrenoceptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert opinion on drug safety 23 (7) (2024)
Ashley Wang, Alexandra Tsivitis, Sijia Ma, Zhaosheng Jin, Ehab Al Bizri, Robert Moore
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants. Expert opinion on drug safety 23 (7) (2024)
Wei Dou, Xin Liu, Pengjiao An, Wei Zuo, Bo Zhang
Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report. Expert opinion on drug safety 23 (7) (2024)
Timothy Tanzer, Betty Pham, Nicola Warren, Michael Barras, Steve Kisely, Dan J Siskind
Overcoming clozapine's adverse events: a narrative review of systematic reviews and meta-analyses. Expert opinion on drug safety 23 (7) (2024)
Joylin Emelia Suares, Saad Khan, Aadrika Aadrika, Pooja Gopal Poojari, Muhammed Rashid, Girish Thunga
Vaccine-associated paralytic poliomyelitis in oral polio vaccine recipients: disproportionality analysis using VAERS and systematic review. Expert opinion on drug safety 23 (7) (2024)
Pingan Peng, Yiwen Chen, Guang Yang, Mingzhao Qin, Xiaohan Xu, Yujie Zhou
Glass bead-activated clotting time (gb-ACT) for monitoring the anticoagulation effects in elderly patients with high risk of venous thromboembolism (VTE). Expert opinion on drug safety 23 (7) (2024)
Joylin Emelia Suares, Saad Khan, Aadrika Aadrika, Pooja Gopal Poojari, Muhammed Rashid, Girish Thunga
Vaccine-associated paralytic poliomyelitis in oral polio vaccine recipients: disproportionality analysis using VAERS and systematic review. Expert opinion on drug safety 23 (7) (2024)
André J Scheen
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile. Expert opinion on drug safety 23 (7) (2024)
Wei Dou, Xin Liu, Pengjiao An, Wei Zuo, Bo Zhang
Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report. Expert opinion on drug safety 23 (7) (2024)
Guixiang Chen, Li Zhang, Si-Ting Zhao, Hao Huang, Zhiwen Fu
Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study. Expert opinion on drug safety 23 (7) (2024)

volume 23, number 8, 2024

Yi Zhao, Zelin Li, Kanghuai Zhang, Na Wang
Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. Expert opinion on drug safety 23 (8) (2024)
Liupu Zheng, Mengqian Ye, Jun Ma, Chen Jin, Yan Yang, Haoqi Li, Rongyuan Zheng, Yi Wang
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis. Expert opinion on drug safety 23 (8) (2024)
Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard, Matthieu Roustit, Charles Khouri
Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic. Expert opinion on drug safety 23 (8) (2024)
Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard, Matthieu Roustit, Charles Khouri
Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic. Expert opinion on drug safety 23 (8) (2024)
Aayushi Sood, Malak Munir, Omar Syed, Vidhi Mehta, Ravleen Kaur, Arathi Kumar, Archana Sridhar, Akshit Sood, Rahul Gupta
An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors. Expert opinion on drug safety 23 (8) (2024)
Liupu Zheng, Mengqian Ye, Jun Ma, Chen Jin, Yan Yang, Haoqi Li, Rongyuan Zheng, Yi Wang
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis. Expert opinion on drug safety 23 (8) (2024)
Michele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, Manfred Hauben
The evolving role of disproportionality analysis in pharmacovigilance. Expert opinion on drug safety 23 (8) (2024)
Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, Ida Carmosino, Claudia Ielo, Alessandro Costa, Lorenzo Torrieri, Matteo Totaro, Maurizio Martelli, Massimo Breccia
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety. Expert opinion on drug safety 23 (8) (2024)